PŘEHLEDOVÉ ČLÁNKY / REVIEW ARTICLES Terapeutické monitorování léčiv – cesta k efektivnější antibiotické terapii. Praktické zkušenosti Fakultní nemocnice | 89 / Anest intenziv Med. 2025;36(2):84-90 / ANESTEZIOLOGIE A INTENZIVNÍ MEDICÍNA www.aimjournal.cz PROHLÁŠENÍ AUTORŮ: Prohlášení o původnosti: Práce je původní a nebyla publikována ani není zaslána k recenznímu řízení do jiného média. Střet zájmů: Autoři prohlašují, že nemají střet zájmů v souvislosti s tématem práce. Podíl autorů: Všichni autoři rukopis četli, souhlasí s jeho zněním a zasláním do redakce časopisu Anesteziologie a intenzivní medicína. VJ, AŠ, MH psaní rukopisu. Financování: Podpořeno grantem SV Lékařské fakulty Masarykovy univerzity: MUNI/A/1689/2024; a Fakultní nemocnicí Brno, grantem MZ ČR – RVO (FNBr, 65269705). Projednání etickou komisí: irrelevantní. LITERATURA 1. Kollef MH, Shorr AF, Bassetti M, Timsit JF, Micek ST, Michelson AP, et al. Timing of antibiotic therapy in the ICU. Crit Care. 2021 Oct 15;25(1):360. doi: 10.1186/s13054-02103787-z. PMID: 34654462; PMCID: PMC8518273. 2. Al‑Shaer MH, Rubido E, Cherabuddi K, Venugopalan V, Klinker K, Peloquin C. Early therapeutic monitoring of β‑lactams and associated therapy outcomes in critically ill patients. J Antimicrob Chemother. 2020 Dec 1;75(12):3644-3651. doi: 10.1093/jac/ dkaa359. PMID: 32910809. 3. Pai Mangalore R, Ashok A, Lee SJ, Romero L, Peel TN, Udy AA, et al. Beta‑Lactam Antibiotic Therapeutic Drug Monitoring in Critically Ill Patients: A Systematic Review and Meta‑Analysis. Clin Infect, DiS. 2022 Nov 14;75(10):1848-1860. doi: 10.1093/cid/ciac506. PMID: 35731853; PMCID: PMC9662173. 4. Sadilova K, Halacova M, Cerny D. Pharmacokinetic Aspects Of Beta‑Lactam Antibiotic Therapy In Intensive Care Unit Patients: A One‑Center Experience With Tdm. Ceska A Slovenska Farmacie: Casopis Ceske Farmaceuticke Spolecnosti A Slovenske Farmaceuticke Spolecnosti. 2020; 69:17-23. 5. Claus BO, Hoste EA, Colpaert K, Robays H, Decruyenaere J, De Waele JJ. Augmented renal clearance is a common finding with worse clinical outcome in critically ill patients receiving antimicrobial therapy. J Crit Care. 2013 Oct;28(5):695-700. doi: 10.1016/j. jcrc.2013.03.003. Epub 2013 May 14. PMID: 23683557. 6. Roberts JA, De Waele JJ, Dimopoulos G, Koulenti D, Martin C, Montravers P, et al. DALI: Defining Antibiotic Levels in Intensive care unit patients: a multi‑centre point of prevalence study to determine whether contemporary antibiotic dosing for critically ill patients is therapeutic. BMC Infect, DiS. 2012 Jul 6;12:152. doi: 10.1186/14712334-12-152. PMID: 22768873; PMCID: PMC3506523. 7. Guilhaumou R, Benaboud S, Bennis Y, Dahyot‑Fizelier C, Dailly E, Gandia P, et al. Optimization of the treatment with beta‑lactam antibiotics in critically ill patients ‑guidelines from the French Society of Pharmacology and Therapeutics (Société Française de Pharmacologie et Thérapeutique‑SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Société Française d’Anesthésie et Réanimation ‑SFAR). Crit Care. 2019 Mar 29;23(1):104. doi: 10.1186/s13054-019-2378-9. PMID: 30925922; PMCID: PMC6441232. 8. Gaur P, Hada V, Rath RS, Mohanty A, Singh P, Rukadikar A. Interpretation of Antimicrobial Susceptibility Testing Using European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Clinical and Laboratory Standards Institute (CLSI) Breakpoints: Analysis of Agreement. Cureus. 2023 Mar 31;15(3):e36977. doi: 10.7759/cureus.36977. PMID: 37139290; PMCID: PMC10149341. 9. Tran NN, Mynatt RP, Kaye KS, Zhao JJ, Pogue JM. Clinical Outcomes With Extended Versus Intermittent Infusion of Anti‑Pseudomonal Beta‑Lactams in Patients With Gram‑Negative Bacteremia. Open Forum Infect, DiS. 2023 Mar 27;10(4):ofad170. doi: 10.1093/ofid/ofad170. Erratum in: Open Forum Infect, DiS. 2023 Jun 13;10(6):ofad309. doi: 10.1093/ofid/ofad309. PMID: 37125229; PMCID: PMC10135424. 10. Abdul‑Aziz MH, Lipman J, Akova M, Bassetti M, De Waele JJ, Dimopoulos G, et al; DALI Study Group. Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort. J Antimicrob Chemother. 2016 Jan;71(1):196-207. doi: 10.1093/jac/dkv288. Epub 2015 Oct 3. PMID: 26433783. 11. Roberts JA, Paul SK, Akova M, Bassetti M, De Waele JJ, Dimopoulos G, et al; DALI Study. DALI: defining antibiotic levels in intensive care unit patients: are current β‑lactam antibiotic doses sufficient for critically ill patients? Clin Infect, DiS. 2014 Apr;58(8):107283. doi: 10.1093/cid/ciu027. Epub 2014 Jan 14. PMID: 24429437. 12. Dulhunty JM, Brett SJ, De Waele JJ, Rajbhandari D, Billot L, Cotta MO, et al; BLING III Study Investigators. Continuous vs Intermittent β‑Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis: The BLING III Randomized Clinical Trial. JAMA. 2024 Aug 27;332(8):629-637. doi: 10.1001/jama.2024.9779. PMID: 38864155; PMCID: PMC11170452. 13. Karaba SM, Cosgrove SE, Lee JH, Fiawoo S, Heil EL, Quartuccio KS, et al. Extended ‑Infusion β‑Lactam Therapy, Mortality, and Subsequent Antibiotic Resistance Among Hospitalized Adults With Gram‑Negative Bloodstream Infections. JAMA Netw Open. 2024 Jul 1;7(7):e2418234. doi: 10.1001/jamanetworkopen.2024.18234. PMID: 38954416; PMCID: PMC11220563. 14. Lexidrug U. Multinational/Drugs 2025. Verze 8. 4. 2 (862) [cited 7. 2. 2025]. 15. Schoenenberger‑Arnaiz JA, Ahmad‑Diaz F, Miralbes‑Torner M, Aragones‑Eroles A, Cano‑Marron M, Palomar‑Martinez M. Usefulness of therapeutic drug monitoring of piperacillin and meropenem in routine clinical practice: a prospective cohort study in critically ill patients. Eur J Hosp Pharm. 2020 Mar;27(e1):e30-e35. doi: 10.1136/ejhpharm-2018-001713. Epub 2019 Feb 27. PMID: 32296502; PMCID: PMC7147564. 16. Scharf C, Paal M, Schroeder I, Vogeser M, Draenert R, Irlbeck M, Zoller M, Liebchen U. Therapeutic Drug Monitoring Of Meropenem And Piperacillin In Critical Illness‑Experience And Recommendations From One Year In Routine Clinical Practice. Antibiotics‑Basel. 2020; 9. 10. 3390/Antibiotics9030131. 17. Imani S, Buscher H, Marriott D, Gentili S, Sandaradura I. Too much of a good thing: a retrospective study of β‑lactam concentration‑toxicity relationships. J Antimicrob Chemother. 2017 Oct 1;72(10):2891-2897. doi: 10.1093/jac/dkx209. PMID: 29091190. 18. Quinton M, Bodeau S, Kontar L, Zerbib Y, Maizel J, Slama M, et al. Neurotoxic Concentration Of Piperacillin During Continuous Infusion In Critically Ill 356 Patients. Antimicrob Agents Chemother. 2017;61:e00654-17. 19. Thalhammer F, Hörl W. Pharmacokinetics of meropenem in patients with renal failure and patients receiving renal replacement therapy. Clin Pharmacokinet. 2000;39:271-279.20 20. Hong L, Downes K, Fakhriravari A, Abdul-Mutakabbir J, Kuti J, Jorgensen S, et al. International consensus recommendations for the use of prolonged-infusion beta- -lactam antibiotics: endorsed by the American College of Clinical Pharmacy, British Society for Antimicrobial Chemotherapy, Cystic Fibrosis Foundation, European Society of Clinical Microbiology and Infectious Diseases, Infectious Diseases Society of America, Society of Critical Care Medicine, and Society of Infectious Diseases Pharmacists: an executive summary. Pharmacotherapy. 2023;43:736-739 21. Wong G, Briscoe S, McWhinney B, Ally M, Ungerer J, Lipman J, et al. Therapeutic drug monitoring of β‑lactam antibiotics in the critically ill: direct measurement of unbound drug concentrations to achieve appropriate drug exposures. J Antimicrob Chemother. 2018 Nov 1;73(11):3087-3094. doi: 10.1093/jac/dky314. PMID: 30137377. 22. Roger C, Louart B. Beta‑Lactams Toxicity in the Intensive Care Unit: An Underestimated Collateral Damage? Microorganisms. 2021 Jul 14;9(7):1505. doi: 10.3390/microorganisms9071505. PMID: 34361942; PMCID: PMC8306322. 23. Khole AV, Dionne E, Zitek‑Morrison E, Campion M. Cefepime extended infusion versus intermittent infusion: Clinical and cost evaluation. Antimicrob Steward Healthc Epidemiol. 2023 Jul 10;3(1):e119. doi: 10.1017/ash.2023.179. PMID: 37502254; PMCID: PMC10369431. 24. Payne LE, Gagnon DJ, Riker RR, Seder DB, Glisic EK, Morris JG, et al. Cefepime ‑induced neurotoxicity: a systematic review. Crit Care. 2017 Nov 14;21(1):276. doi: 10.1186/s13054-017-1856-1. PMID: 29137682; PMCID: PMC5686900. 25. Venugopalan V, Casaus D, Kainz L, Slaton CN, Hurst N, Bruzzone M, et al. Use of therapeutic drug monitoring to characterize cefepime‑related neurotoxicity. Pharmacotherapy. 2023 Jan;43(1):6-14. doi: 10.1002/phar.2744. Epub 2022 Dec 2. PMID: 36401796. 26. Lodl EF, Alshaer MH, Adams CB, Richards A, Peloquin C, Venugopalan V. Utilization of cefepime therapeutic drug monitoring in febrile neutropenia patients with hematologic malignancies. J Oncol Pharm Pract. 2024 Oct;30(7):1207-1213. doi: 10.1177/10781552231213883. Epub 2023 Nov 19. PMID: 37981806. 27. Rao GG, Konicki R, Cattaneo D, Alffenaar JW, Marriott DJE, Neely M; IATDMCT Antimicrobial Scientific Committee. Therapeutic Drug Monitoring Can Improve Linezolid Dosing Regimens in Current Clinical Practice: A Review of Linezolid Pharmacokinetics and Pharmacodynamics. Ther Drug Monit. 2020 Feb;42(1):83-92. doi: 10.1097/ FTD.0000000000000710. PMID: 31652190. 28. Thirot H, Fage D, Leonhardt A, Clevenbergh P, Besse‑Hammer T, Yombi J, et al. Towards A Better Detection Of Patients At‑Risk Of Linezolid Toxicity In Clinical Practice: A Prospective Study In Three Belgian Hospital Centers. Frontiers In Pharmacology. 2024; 15. 10. 3389/Fphar.2024.1310309. 29. Inoue Y, Kashiwagi H, Sato Y, Nashimoto S, Sugawara M, Takekuma Y. Exploring the impact of baseline platelet count on linezolid‑induced thrombocytopenia: a retrospective single‑center observation study. Int J Clin Pharm. 2025 Feb;47(1):90-98. doi: 10.1007/s11096-024-01810-1. Epub 2024 Oct 4. PMID: 39365521. 30. Lin B, Hu Y, Xu P, Xu T, Chen C, He L, et al. Expert consensus statement on therapeutic drug monitoring and individualization of linezolid. Front Public Health. 2022 Aug 10;10:967311. doi: 10.3389/fpubh.2022.967311. PMID: 36033811; PMCID: PMC9399604. 31. Lau C, Marriott D, Bui J, Figtree M, Gould M, Chubaty A, et al. LInezolid Monitoring to MInimise Toxicity (LIMMIT1): A multicentre retrospective review of patients receiving linezolid therapy and the impact of therapeutic drug monitoring. Int J Antimicrob Agents. 2023 May;61(5):106783. doi: 10.1016/j.ijantimicag.2023.106783. Epub
RkJQdWJsaXNoZXIy NDA4Mjc=